Introduction
============

Essential fatty acids are important constituents of all cell membranes and influence both inflammatory and atherosclerotic processes. The essential fatty acids *cis*-linoleic acid (LA;18: 2 ω-6) and α-linolenic acid (ALA; 18:3 ω-3) are metabolized to arachidonic acid (AA; 20:4 ω-6) and eicosapentaenoic acid (EPA; 20:5 ω-3), respectively, by delta-5 (D5D) and delta-6 (D6D) desaturases (Das, [@B9]; Figure [1](#F1){ref-type="fig"}). Since most of the products of the arachidonic acid pathway have pro-inflammatory effects, increased D5D and D6D activity in the ω-6 pathway may promote systemic inflammation and increase the risk of atherosclerosis (Das, [@B9]; Allayee et al., [@B1]; Martinelli et al., [@B23]). Conversely, increased activities of these desaturases could stimulate the synthesis of EPA (which has anti-inflammatory properties) from ALA, counteracting the effects of AA synthesis. However, both EPA and AA are synthesized at very low rates *in vivo* (Harris et al., [@B16]; Mozaffarian et al., [@B28]).

![**Metabolism of essential fatty acids**.](fgene-03-00086-g001){#F1}

Diet, metabolism, and genetic variation influence the fatty acid composition of the plasma lipids and cell membranes. The variation in plasma and dietary fatty acids, particularly polyunsaturated fatty acids (PUFAs), has been shown to be under considerable genetic influence (Cai et al., [@B8]; Tanaka et al., [@B37]; Voruganti et al., [@B39]). Recent genome-wide association studies (GWAS) have shown a strong association between PUFAs and single-nucleotide polymorphisms (SNPs) in fatty acid desaturase 1 and 2 (*FADS1* and *FADS2*) genes, which code for D5D and D6D, respectively (Tanaka et al., [@B37]). These associations have been further confirmed by candidate gene studies in various populations (Schaeffer et al., [@B33]; Malerba et al., [@B22]; Martinelli et al., [@B24]; Lattka et al., [@B21], [@B20]; Rzehak et al., [@B32]; Bokor et al., [@B6]; Glaser et al., [@B13]; Mathias et al., [@B25]; Merino et al., [@B26]). In addition, these GWAS have found association between *FADS1* and *FADS2* SNPs and cardiovascular disease (CVD) risk factors (Tanaka et al., [@B37]). Both genes are located on chromosome 11q12-q13.1. Genome-wide linkage and association studies have been conducted with plasma fatty acids (Schaeffer et al., [@B33]; Malerba et al., [@B22]; Martinelli et al., [@B24]; Lattka et al., [@B21], [@B20]; Rzehak et al., [@B32]; Bokor et al., [@B6]; Glaser et al., [@B13]; Mathias et al., [@B25]; Voruganti et al., [@B39]; Merino et al., [@B26]), but few studies have investigated genetic influences on estimated desaturase activities in blood (Martinelli et al., [@B24]; Bokor et al., [@B6]; Mathias et al., [@B25]; Merino et al., [@B26]).

Westernized diets are characterized by higher amounts of ω-6 PUFA more inclined to promote pro-inflammatory activities in contrast to ω-3 PUFA (Allayee et al., [@B1]; Martinelli et al., [@B23]). The Alaskan Eskimo population, which is transitioning away from an ω-3 fatty acid-rich diet to a relatively westernized diet, is thus at a higher risk for systemic inflammation and atherosclerosis. Given these facts and the importance of D5D and D6D in essential fatty acid metabolism and inflammation, we investigated the genetic influence on estimated D5D and D6D desaturase activities. Herein we present the results of a genome-wide scan and candidate SNP analyses for estimated D5D and D6D activities in Alaskan Eskimos participating in the genetics of coronary artery disease in Alaska Natives (GOCADAN) study.

Materials and Methods
=====================

Study design
------------

In the GOCADAN study, 1214 individuals (all 18 years of age and older) were recruited from villages in the Norton Sound region on the northwestern coast of Alaska. Details of the study recruitment, design, and methods have been reported by Howard et al. ([@B18]); Ebbesson et al. ([@B12]). The Institutional Review Boards from all participating institutions approved this study and informed consent was obtained from all participants.

Demographic and phenotypic data
-------------------------------

Demographic and genealogical data collected during the interviews included name, gender, date and place of birth, current home of the participant and his or her spouse, and first-degree relatives of all household members. Anthropometric measurements, height, weight, and waist and hip circumference, were measured by standardized procedures. Body mass index (BMI) was calculated by dividing weight (kilograms) by height (meters) squared. Body fat was measured using a Quantum II bioelectrical body composition analyzer (RJL Systems, Clinton Township, MI). Triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol were measured using an auto analyzer (Hitachi 717, Amposta, Spain). Heart rate was measured via computerized ECG (electrocardiograph; GE Systems MAC 1200), with the participant at rest. Heart rate was calculated using the mean interval between QRS complexes during a 10-s period. Apolipoprotein A1 (ApoA1) was analyzed by immunoprecipitation assay.

Of the 1214 individuals participating in the study, fatty acid concentrations and desaturases data were available for 761 individuals (\>35 years of age). Total plasma and erythrocyte fatty acid concentrations were estimated following the methods previously described by Ebbesson et al. ([@B10]) and Ebbesson et al. ([@B11]), respectively. In short, analysis of the composition of fatty acids was performed on a Hewlett Packard 5890 gas chromatograph equipped with a 60 m × 0.25 mm SP330 capillary column chemically bonded with 0.25 μm liquid phase and a flame ionization detector. Structural confirmation was determined by mass spectrometry using a Varian 2000 ion trap detector. Each fatty acid measure was computed using a regression equation in which the ratio of the area of each fatty acid peak to the internal standard was plotted against the weight ratio of the fatty acid and the internal standard. All fatty acids are expressed as percentages (mol/100 ml of total fatty acids).

Desaturases in plasma and erythrocytes were estimated by product-precursor ratio of PUFAs (Warensjö et al., [@B40]).

D5D = \[(20:4 ω-6)/(20:3 ω-6)\]

D6D = \[(18:3 ω-6)/(18:2 ω-6)\]

Genotype data
-------------

For each of the participants, 400 short tandem repeat (STR) markers (spaced at an average interval of 10 cM throughout the genome) were amplified from genomic DNA in separate polymerase chain reactions (PCR) using fluorescently labeled primer pairs (ABI PRISM Linkage Mapping Set MD 10 Version 2, Applied Biosystems, Foster City, CA, USA). Pedigree and Mendelian errors were detected and corrected utilizing the software pedigree relationship statistical tests (PREST) and SIMWALK (Sobel and Lange, [@B35]). Multipoint identity-by-descent (IBD) matrices for genome-wide linkage analyses were calculated using the linkage analysis package LOKI (Heath, [@B17]). The chromosomal map (Haldane) used in these computations was based on marker locations reported by DeCode genetics (Kong et al., [@B19]).

SNP selection and genotyping
----------------------------

We genotyped 324 SNPs clustered in the candidate genes within the one-logarithm of odds (LOD) support interval of our quantitative trait locus (QTL) region (26 in *FADS1*, 100 in *FADS2*, 149 in carnitine palmitoyl transferase 1A, liver (*CPT1A*), and 49 in 7-dehydrocholesterol reductase (*DHCR7*)). These SNPs were selected to be within 2 kb upstream to 1 kb downstream of each gene and were previously reported to be polymorphic in both Asian and European populations. Of the 324 SNPs included in data collection, 34 failed and 78 were not polymorphic in our study population, leaving 212 polymorphic markers for analysis (*FADS1* = 16, *FADS2 *= 68, *DHCR7 *= 30, and *CPT1A *= 98). SNPs were typed using the multiplex VeraCode technology from Illumina according to the manufacturer's protocol (Illumina, San Diego, CA, USA).

Details of the technology are given in Voruganti et al. ([@B39]). Briefly, the technology is based on allele-specific primer extension. Genomic DNA (250 ng) was chemically activated, labeled with biotin, and then hybridized to a pool of locus-specific oligos. After primer extension and ligation, a PCR reaction was performed using a flurorescent-labeled primers, followed by hybridization to VeraCode beads. The beads were then scanned on a BeadXpress reader using the VeraScan software (Illumina). Genotype calls were generated by analyzing the raw data using the software BeadStudio (Illumina).

Statistical analyses
--------------------

### Univariate genetic analysis

A variance components decomposition method was used to estimate heritability and detect linkage to chromosomal locations affecting variation in estimated plasma and erythrocyte desaturase activities via genome-wide linkage analysis. This method was implemented in the software program SOLAR and has been described in detail elsewhere (Blangero and Almasy, [@B3]; Almasy and Blangero, [@B2]). Before conducting genetic analyses, distributional properties of all traits were evaluated. All values greater than four standard deviations from the mean were removed and the remaining traits were transformed by inverse normalization to meet assumptions of normality. All analyses were conducted adjusting for age, sex, diabetes status, and use of lipid-lowering medication.

### Measured genotype analysis (MGA)

Genotype frequencies for each SNP were calculated using a maximum-likelihood estimation method and were tested for departures from Hardy--Weinberg equilibrium. Estimates of linkage disequilibrium (LD) between SNPs were determined by calculating pair-wise D′ and *r*^2^ statistics. As a first step in investigating the association between the SNPs in candidate genes and variation in estimated desaturase activities, we employed MGA implemented in SOLAR (Boerwinkle et al., [@B5]). This approach extends the classical variance components-based biometrical model to account for both the random effects of kinship and the main effects of SNP genotypes. For each SNP, we compared this saturated model with a null model in which the main effect of the SNP is constrained to zero. The test statistic, twice the difference in log~e~ (likelihood) between the saturated model and the SNP-specific null, has a chi-square distribution with one degree of freedom.

### Bayesian quantitative trait nucleotide analysis

The measured genotype analysis described above was used to assess association between the trait and each SNP, analyzing one SNP at a time. However, multiple functional variants will often exist within a chromosomal locus, and joint analysis of multiple variants may be more powerful to detect their effects and to establish which of the many polymorphisms within a region are the most likely to be functional. Blangero et al. ([@B4]) developed the Bayesian quantitative trait nucleotide (BQTN) approach, which is essentially a Bayesian method based on an underlying measured genotype model that permits joint analysis of multiple variants. The BQTN analysis was implemented in SOLAR to identify the functional SNPs that are statistically most likely to be associated with a phenotype. This method has been described in detail elsewhere (Blangero et al., [@B4]).

### Conditional linkage analysis

Linkage analysis (Sun et al., [@B36]) for estimated erythrocyte D5D was performed conditional on SNPs that showed statistical evidence of functionality. If the SNP or SNPs account for the linkage signal completely, the LOD score will be reduced to zero.

SNP Genotyping and Identification and Analysis of Expression Transcripts in Mexican Americans
---------------------------------------------------------------------------------------------

The SNPs selected for replication were part of the GWAS conducted in the San Antonio Family Heart Study (SAFHS). The SAFHS, a study initiated in 1991, focuses on identifying genetic and environmental risk factors for CVD in Mexican Americans without regard to disease status. GWAS was conducted with SNPs obtained using Illumina HumanHap550 genotyping BeadChip (Illumina Inc., San Diego, CA). Lymphocyte expression data were available for 1240 individuals participating in the SAFHS. However, data on both transcripts and SNPs were available for 1189 individuals. Details of identification and analysis of transcripts are given in Göring et al. ([@B15]). Measured genotype analysis was conducted to analyze the association of *FADS1*, *FADS2*, and *CPT1A* SNPs and their *cis*-regulated transcripts and CVD-related traits in Mexican Americans.

Results
=======

Estimation of heritability and localization of QTLs
---------------------------------------------------

Erythrocyte and plasma D5D and D6D activities were significantly heritable (Table [1](#T1){ref-type="table"}), with values ranging between 0.50 and 0.90. Genome-wide linkage scans for D5D and D6D revealed a QTL with strong linkage on chromosome 11 for estimated erythrocyte D5D (Figure [1](#F1){ref-type="fig"}). This QTL was localized to chromosome 11q12-q13 near marker *D11S987* with a LOD score of 3.5 (Table [1](#T1){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). The one-LOD support interval for this QTL spanned approximately 20 cM between markers *D11S4191* and *D11S1314*. This interval contains promising candidate genes including the *FADS1* gene that codes for D5D. Other candidate genes in this interval are *FADS2*, *DHCR7*, and *CPT1A*.

###### 

**Heritabilities and linkage results for D5D and D6D[\*](#tfn1){ref-type="table-fn"}**.

  Trait             Mean (SD)        *h*^2^ (SE)    *p*-Value      Chr   Location (cM)   LOD score
  ----------------- ---------------- -------------- -------------- ----- --------------- -----------
  **PLASMA**                                                                             
  D5D               0.683 (0.30)     0.502 (0.15)   0.00036        3     97              1.615
  D6D               0.0187 (0.01)    0.897 (0.22)   0.000275       2     174             1.569
  **ERYTHROCYTE**                                                                        
  D5D               8.015 (2.6)      0.544 (0.11)   0.0000003      11    82              3.53
  D6D               0.0069 (0.003)   0.649 (0.12)   7.4 × 10^−9^   2     35              1.43

*\*Age, sex, diabetes status, and lipid medication were used as covariates*.

![**Genome-wide linkage analysis for erythrocyte D5D localizes a QTL on chromosome 11**. The QTL for plasma and erythrocyte D5D estimates on chromosome 11. Solid line, erythrocyte D5D (LOD = 3.5 at 82 cM); dashed line, plasma D5D (LOD = 0.9 at 81 cM).](fgene-03-00086-g002){#F2}

Measured genotype analysis
--------------------------

Linkage disequilibrium patterns of these SNPs are shown in Figure S1 in Supplementary Material. All of the SNPs were tested for association with estimated erythrocyte and plasma D5D and D6D and their individual components. Polymorphisms in *FADS1*, *FADS2*, and *CPT1A* showed strong association with erythrocyte and plasma D5D and D6D (Figure [3](#F3){ref-type="fig"}). Estimated erythrocyte D5D and its components 20:3 ω-6 and 20:4 ω-6 showed the strongest association, with *p*-values ranging from 10^−28^ to 10^−5^ (Table [2](#T2){ref-type="table"}). Similarly, estimated plasma D5D and its components, used to estimate the ratio, showed significant associations with SNPs in the three genes (*p*-values 10^−39^ to 10^−16^). However, the association of plasma 20:3 ω-6 with these SNPs was not significant after adjusting for multiple testing. For estimated plasma D6D, only the association with SNPs in the *FADS1* and *FADS2* genes was significant, whereas association with erythrocyte D6D was significant for SNPs in all three genes (Table [3](#T3){ref-type="table"}). Detailed results of the association with estimated plasma and erythrocyte D5D and D6D activities and their individual components are shown in Tables S1 and S2 in Supplementary Material.

![**Manhattan plots showing the association of SNPs on CPT1A and FADS1 and FADS2 with erythrocyte D5D**. **(A)** *CPT1A* and **(B)** *FADS1*and *FADS2*.](fgene-03-00086-g003){#F3}

###### 

**Measured genotype association results for SNPs most significantly associated with D5D**.

  Gene      SNP          Minor allele (frequency)   MGA (*p*-value)[\*](#tfn2){ref-type="table-fn"}                                                                                  
  --------- ------------ -------------------------- ------------------------------------------------- ------------------- ------------------- ------------------- ------------------ -------------------
  *FADS1*   rs174541     A (0.113)                  **2.2 × 10^−26^**                                 **1.8 × 10^−5^**    **8.1 × 10^−28^**   **1.2 × 10^−28^**   **8.8 × 10^−3^**   **8.5 × 10^−16^**
            rs174546     G (0.114)                  **1.5 × 10^−24^**                                 **2.7 × 10^−5^**    **4.3 × 10^−26^**   **3.6 × 10^−28^**   0.009              **2.4 × 10^−15^**
            rs174556     G (0.122)                  **2.2 × 10^−26^**                                 **1.1 × 10^−26^**   **8.1 × 10^−28^**   **1.3 × 10^−28^**   0.009              **8.9 × 10^−16^**
  *FADS2*   rs1535       A (0.116)                  **1.9 × 10^−25^**                                 **1.5 × 10^−5^**    **2.5 × 10^−27^**   **2.3 × 10^−29^**   0.012              **2.8 × 10^−16^**
            rs174568     G (0.115)                  **1.1 × 10^−25^**                                 **9.5 × 10^−6^**    **2.2 × 10^−27^**   **7.7 × 10^−30^**   0.040              **1.7 × 10^−24^**
            rs174570     G (0.161)                  **1.3 × 10^−28^**                                 0.009               **8.2 × 10^−21^**   **1.4 × 10^−34^**   0.015              **1.2 × 10^−19^**
            rs174576     C (0.116)                  **7.1 × 10^−25^**                                 **8.5 × 10^−6^**    **5.1 × 10^−27^**   **2.0 × 10^−28^**   0.012              **2.3 × 10^−16^**
            rs174579     G (0.426)                  0.0004                                            **9.9 × 10^−7^**    **1.9 × 10^−11^**   **6.1 × 10^−9^**    0.866              **5.7 × 10^−6^**
            rs968567     A (0.038)                  0.096                                             0.0003              0.032               0.023               0.625              0.042
  *CPT1A*   rs11228368   G (0.138)                  **2.0 × 10^−13^**                                 0.0004              **5.2 × 10^−16^**   **3.3 × 10^−23^**   0.157              **1.6 × 10^−16^**
            rs3019594    A (0.217)                  **2.2 × 10^−27^**                                 **1.1 × 10^−5^**    **1.3 × 10^−27^**   **6.6 × 10^−39^**   0.040              **1.7 × 10^−24^**
            rs613084     A (0.065)                  **7.2 × 10^−13^**                                 0.054               **1.6 × 10^−9^**    **3.2 × 10^−11^**   0.037              **2.1 × 10^−7^**

*\**p*-Values \<0.0002 are considered significant after adjusting for multiple testing. These are depicted in bold*.

###### 

**Measured genotype association results for SNPs with D6D**.

  Gene      SNP          MGA (*p*-value)[\*](#tfn3){ref-type="table-fn"}                                                            
  --------- ------------ ------------------------------------------------- ------------------- ------------------- ------- -------- ------------------
  *FADS1*   rs174541     **0.00017**                                       **2.3 × 10^−9^**    **1.1 × 10^−12^**   0.003   0.003    **2.6 × 10^−5^**
            rs174546     0.0005                                            **1.3 × 10^−9^**    **4.8 × 10^−12^**   0.004   0.0008   **4.8 × 10^−5^**
            rs174556     **0.00016**                                       **6.8 × 10^−9^**    **2.0 × 10^−12^**   0.005   0.0016   **4.0 × 10^−5^**
  *FADS2*   rs1535       0.00029                                           **2.1 × 10^−9^**    **3.1 × 10^−12^**   0.003   0.0018   **2.6 × 10^−5^**
            rs174568     2.7 **× **10^−4^                                  **2.4 × 10^−9^**    **3.1 × 10^−12^**   0.003   0.002    **2.6 × 10^−5^**
            rs174570     0.0033                                            **2.8 × 10^−11^**   **6.1 × 10^−11^**   0.056   0.002    0.0010
            rs174576     0.00033                                           **2.2 × 10^−9^**    **4.3 × 10^−12^**   0.003   0.0007   **2.6 × 10^−5^**
            rs174579     0.232                                             **0.0028**          0.932               0.960   0.171    0.239
            rs968567     0.497                                             0.039               0.747               0.051   0.577    0.233
  *CPT1A*   rs11228368   0.221                                             **3.8 × 10^−6^**    0.423               0.860   0.009    0.181
            rs3019594    0.469                                             **5.4 × 10^−12^**   0.012               0.560   0.0015   0.043
            rs613084     0.119                                             **8.2 × 10^−6^**    **6.7 × 10^−5^**    0.881   0.086    0.301

*\**p*-Values \<0.0002 are considered significant after adjusting for multiple testing. These are depicted in bold*.

These SNPs were also tested for their association with cardiovascular risk factors, heart rate, plaque, triglycerides, HDL, LDL, and total cholesterol. SNPs in all three genes were associated with heart rate and HDL cholesterol (Table [4](#T4){ref-type="table"}). However, after adjusting for multiple testing, only the association with heart rate remained significant. Individuals with minor alleles of these genes had a lower heart rate.

###### 

**Measured genotype association (MGA) results for SNPs with CVD-related phenotypes**.

  Gene      SNP          MGA (*p*-value)[\*](#tfn4){ref-type="table-fn"}                                                                  
  --------- ------------ ------------------------------------------------- ------- ------- ------------------ ------- ------------------- -------
  *FADS1*   rs174541     0.010                                             0.623   0.120   0.0003             0.672   **2.9 × 10^−5^**    0.808
            rs174546     0.011                                             0.685   0.192   0.00057            0.565   **1.9 × 10^−5^**    0.856
            rs174556     0.003                                             0.455   0.095   **9.0 × 10^−5^**   0.794   **1.6 × 10^−5^**    0.775
  *FADS2*   rs1535       0.015                                             0.646   0.128   0.00047            0.665   **1.0 × 10^−5^**    0.664
            rs174568     0.016                                             0.697   0.127   0.0006             0.653   **8.5 × 10^−6^**    0.708
            rs174570     0.011                                             0.119   0.234   0.001              0.484   **6.1 × 10^−8^**    0.213
            rs174576     0.010                                             0.679   0.114   0.00037            0.598   **6.9 × 10^−6^**    0.679
            rs174579     0.249                                             0.930   0.508   0.097              0.149   0.0066              0.329
            rs968567     0.510                                             0.155   0.900   0.969              0.094   0.0063              0.143
  *CPT1A*   rs11228368   0.026                                             0.289   0.439   0.057              0.780   **8.6 × 10^−8^**    0.056
            rs3019594    0.001                                             0.088   0.794   0.001              0.729   **2.8 × 10^−10^**   0.206
            rs613084     0.001                                             0.177   0.997   **7.1 × 10^−5^**   0.670   0.0009              0.817

*\**p*-Values \<0.0002 are considered significant after adjusting for multiple testing. These are depicted in bold*.

BQTN analysis
-------------

Because BQTN analysis is designed to identify SNPs that are most likely to have a functional effect on a trait and it is robust to multiple testing, (Boerwinkle et al., [@B5]) the SNPs were next tested by BQTN analysis. In the current analyses, SNPs were utilized after removing SNPs that were in LD (\>90%) with other SNPs. One variant from each gene showed a posterior probability greater than 0.8. SNPs rs174541 from *FADS1* and rs174568 from *FADS2* showed posterior probabilities of 1, indicating a strong probability of having a functional effect on erythrocyte D5D. However, with plasma D5D, rs3019594 of *CPT1A* was the only SNP to show a posterior probability of 1. The genotype-specific phenotype means show minor alleles of all three SNPs to be associated with higher levels of erythrocyte and plasma D5D (Table [5](#T5){ref-type="table"}). None of these SNPs showed posterior probabilities greater than 0.5 for estimated plasma or erythrocyte D6D activities.

###### 

**Bayesian quantitative trait nucleotide analysis for erythrocyte and plasma D5D**.

  Gene              SNP         Location in the gene   Mean effect size   Posterior probability of a functional effect   AA^[a](#tfn5){ref-type="table-fn"}^           AB^[a](#tfn5){ref-type="table-fn"}^   BB^[a](#tfn5){ref-type="table-fn"}^
  ----------------- ----------- ---------------------- ------------------ ---------------------------------------------- --------------------------------------------- ------------------------------------- -------------------------------------
  **ERYTHROCYTE**                                                                                                                                                                                            
  *FADS1*           rs174541    Flanking 3′ UTR        0.168              1                                              7.65 (2.4)^[b](#tfn6){ref-type="table-fn"}^   9.73 (2.1)                            13.56 (3.1)
  *FADS2*           rs174568    Flanking 3′ UTR        0.171              1                                              7.65 (2.4)                                    9.75 (2.1)                            13.56 (3.1)
  *CPT1A*           rs3019594   Intron                 0.172              0.8                                            7.49 (2.2)                                    8.85 (2.4)                            12.40 (3.1)
  **PLASMA**                                                                                                                                                                                                 
  *FADS1*           rs174541    Flanking 3′ UTR        0.168              0.5                                            0.63 (0.3)                                    0.85 (0.3)                            1.47 (0.3)
  *FADS2*           rs174568    Flanking 3′ UTR        0.174              0.6                                            0.63 (0.3)                                    0.86 (0.3)                            1.47 (0.3)
  *CPT1A*           rs3019594   Intron                 0.261              1                                              0.60 (0.3)                                    0.81 (0.3)                            1.19 (0.3)

*^a^A, major allele; B, minor allele*.

*^b^Mean (standard deviation)*.

Conditional linkage
-------------------

A linkage scan conditional on the three SNPs, which showed posterior probability of 0.8 and greater, decreased the LOD score for erythrocyte D5D significantly from 3.5 to 1.5 for *CPT1A* SNP and 1.9 for *FADS1* and *FADS2* SNPs (Figure [4](#F4){ref-type="fig"}).

![**Conditional linkage analysis for erythrocyte D5D on chromosome 11**. Linkage analysis conditional on the most significantly associated SNP in **(A)** *CPT1A*, **(B)** *FADS1*, and **(C)** *FADS2*. Solid line, erythrocyte D5D; dashed line, erythrocyte D5D conditional on SNPs.](fgene-03-00086-g004){#F4}

Examination of *cis*-regulated FADS1, FADS2, and CPT1A transcripts in Mexican Americans
---------------------------------------------------------------------------------------

In a previous study by Göring et al. ([@B15]), linkage analysis was conducted to identify genetic factors that affect the variation in the levels of gene expression. The study identified a number of known *cis*-regulated transcripts with high-magnitude LOD scores. Included among these, *FADS1, FADS2*, and *CPT1A* transcript levels were found to be strongly associated with SNPs located nearby (*cis*) their coding locus, with *p*-values ranging from 10^−75^ to 10^−7^. Just as in the GOCADAN study, these SNPs were also tested for their association with cardiovascular risk factors, heart rate, plaque, triglycerides, HDL, LDL, and total cholesterol in the SAFHS, a large family-based study of genetics of coronary artery disease in Mexican Americans. Nominal associations were obtained between the SNPs and ApoA1, and HDL, LDL, total cholesterol and heart rate in the SAFHS (Table [6](#T6){ref-type="table"}).

###### 

**Measured genotype association results for SNPs with CVD-related phenotypes and *cis*-regulated transcripts in Mexican Americans**.

  Gene      SNP          MGA (*p*-value)[\*](#tfn7){ref-type="table-fn"}                                                   
  --------- ------------ ------------------------------------------------- ------- ------- ------- ------- ------- ------- -------
  *FADS1*   rs174546     **1.23 × 10^−31^**                                0.055   0.044   0.730   0.058   0.163   0.039   0.518
            rs174556     **2.53 × 10^−32^**                                0.094   0.038   0.700   0.090   0.154   0.101   0.619
  *FADS2*   rs1535       **1.89 × 10^−29^**                                0.081   0.069   0.763   0.072   0.241   0.114   0.304
            rs174570     **3.42 × 10^−7^**                                 0.168   0.772   0.710   0.282   0.709   0.041   0.461
            rs174576     **4.45 × 10^−29^**                                0.053   0.041   0.727   0.034   0.184   0.080   0.514
            rs174579     **3.13 × 10^−24^**                                0.316   0.580   0.649   0.406   0.467   0.943   0.394
            rs968567     **2.57 × 10^−75^**                                0.933   0.034   0.333   0.518   0.032   0.370   0.882
  *CPT1A*   rs11228368   **2.43 × 10^−22^**                                0.133   0.506   0.970   0.186   0.306   0.632   0.798
            rs613084     **1.14 × 10^−62^**                                0.281   0.883   0.771   0.234   0.336   0.587   0.821

*\**p*-Values \<0.006 are considered significant after adjusting for multiple testing. These are depicted in bold*.

Discussion
==========

The key finding of this study is the strong statistical support for functional effects of *FADS1, FADS2*, and *CPT1A* SNPs on the variation in estimated erythrocyte and plasma D5D, a rate-limiting enzyme in the conversion of essential fatty acids to AA (20:4 ω-6) and EPA (20; 5 ω-3). High heritability estimates for estimated plasma and erythrocyte D5D and D6D activities observed in this study show that there is a significant genetic influence on their variation. Although no study has so far computed heritabilities for desaturase activities, heritabilities of their individual components have been estimated and have been found to be lower than our desaturase estimates (Tanaka et al., [@B37]; Voruganti et al., [@B39]). Similarly, no linkage studies have been conducted for estimated desaturase activities. A genome-wide scan conducted for plasma and erythrocyte D5D and D6D activities in the current study showed evidence of a highly significant QTL on chromosome 11q12-q13 for estimated erythrocyte D5D. This region has four potential candidate genes, *FADS1*, *FADS2*, *CPT1A*, and *DHCR7*. To follow up on our QTL, we genotyped SNPs in the four potential candidate genes and conducted measured genotype-based association analyses with estimated plasma and erythrocyte D5D and D6D. Desaturases are key enzymes facilitating the introduction of double bonds between carbon atoms of fatty acyl chains in the metabolism of dietary PUFAs (Martinelli et al., [@B23]). Given the dependence of pro- or anti-inflammatory eicosanoid formation on the availability of ω-3 or ω-6 PUFAs, the form of dietary PUFA consumed is critical. In our study group, dietary ω-3 and ω-6 PUFA were found to positively associated with age, with younger individuals consuming more of saturated fatty acid-rich foods indicating a shift away from traditional foods rich in ω-3 FAs.

In the current study, a strong association between the SNPs and estimated plasma and erythrocyte D5D activities was observed. In particular, minor alleles of *FADS1*, *FADS2*, and *CPT1A* SNPs were associated with higher desaturase activity. Few studies have been conducted to examine the association of *FADS1* and *FADS2* SNPs with estimated desaturase activities. Polymorphisms in the *FADS* cluster have been found to be significantly associated with serum estimated D5D and D6D activities in European adolescents and adults from an island population of European descent (Bokor et al., [@B6]; Mathias et al., [@B25]). In contrast to our study, they found minor alleles in *FADS1* and *FADS2* genes to be associated with lower D5D activities. In another study, Martinelli et al. ([@B24]) found *FADS* haplotypes to be associated with higher estimated erythrocyte desaturase activity. Similarly in a study conducted in Caucasian and Asian adults *FADS1* and *FADS2* SNPs were associated with altered desaturase activity (Merino et al., [@B26]). On the other hand, several population studies have reported associations of *FADS* SNPs with PUFAs. In the first of a series of studies, *FADS1* and *FADS2* SNPs were associated with fatty acids in phospholipids in Europeans and accounted for about 28% of the variance in fatty acids (Schaeffer et al., [@B33]). Minor alleles of these genotypes were associated with higher levels of LA18: 2 ω-6 and ALA18: 3 ω-3 and lower levels of AA 20:4 ω-6 and EPA 20:5 ω-3. This study was replicated by Rzehak et al. ([@B32]) in a Bavarian population of Germany. In addition to phospholipids, this study also demonstrated an association between *FADS1* and *FADS2* SNPs and erythrocyte membrane PUFAs. Similarly, PUFAs in erythrocytes and phospholipids were associated with *FADS1* and *FADS2* SNPs in an Italian population (Malerba et al., [@B22]). In these studies, minor alleles were associated with higher ALA levels (Martinelli et al., [@B24]) and lower levels of AA (Malerba et al., [@B22]) in accordance with Schaeffer et al. ([@B33]). However, in our study, minor alleles of all three genes were associated with increased plasma and erythrocyte AA 20:4 ω-6 levels and reduced EPA 20:5 ω-3 levels. The differences observed here may be attributed to the differences in population structure, or LD patterns of the SNPs based on population groups and dietary patterns.

Genetic studies conducted with PUFAs so far have found associations with SNPs on *FADS1* and *FADS2* but not those on *CPT1A*. Studies on desaturases in humans are mostly based on desaturase activity estimates calculated from product:precursor fatty acid ratios. Because most of the lipids in circulation in the fasting state are derived from the liver, these desaturation indices calculated from fasting samples are thought to reflect hepatic desaturase activity (Sjogren et al., [@B34]; Merino et al., [@B27]). Thus, the role of liver-specific CPT1A enzyme in the regulation of liver-specific desaturases, in addition to PUFAs, assumes significance. This is supported by our results, which show strong association of *CPT1A* SNPs with estimated plasma and erythrocyte D5D activities.

The *CPT1A* gene is 60 kb long with 18 coding exons and is known to be modulated by dietary and hormonal factors in tissues such as heart, muscle, and liver (Gobin et al., [@B14]; Bonnefont et al., [@B7]). CPT1A is a liver-specific outer-membrane enzyme that plays a key role in the transport of PUFAs across the mitochondrial membrane and in β-oxidation. Unlike short- and medium-chain fatty acids, PUFAs cannot be transported across the mitochondrial membrane by simple diffusion. The PUFAs are first converted to their co-A esters and in combination with carnitines they are converted to acylcarnitines by CPT1A enzyme and transported across the mitochondrial membrane (Prip-Buus et al., [@B29]). In a study conducted in a Greenland Inuit population, Rajakumar et al. ([@B30]) found that variant P479L of *CPT1A* was very common and was associated with higher levels of HDL and ApoA1 and thus may be protective against atherosclerosis. In a study in Canadians, *CPT1A* and *CPT1B* variants were associated with obesity traits. In addition, the investigators found that the dietary intake of fat seemed to modulate these associations, particularly in individuals who were consuming high-fat diets (Robitaille et al., [@B31]). In another study, haplotypes of *CPT1A* were associated with left ventricular mass in essential hypertension (Tripodi et al., [@B38]). In the current study, the minor alleles of all three genes were associated positively with all CVD risk factors and with both desaturase activity estimates.

The BQTN analysis helps narrow down the variants for further molecular and functional analyses by identifying which SNP has the highest probability of being associated with the phenotype. Our BQTN findings demonstrate with a strong statistical support that SNPs in *FADS1*, *FADS2*, and *CPT1A* genes have either a functional role or they are in high LD with functional variants affecting D5D activities. In addition, the high genetic variance (17--26%) for D5D activities explained by these SNPs show the importance of *FADS1*, *FADS2*, and *CPT1A* gene polymorphisms in the activity of D5D. Furthermore, a linkage analysis conditional on the three SNPs resulted in approximately 60% decrease in the LOD score, indicating that the SNPs accounted for a substantial part of the QTL but did not explain the linkage signal completely.

In an effort to glean further support for the association, we conducted association analyses of *cis*-regulated transcripts of *FADS1*, *FADS2*, and *CPT1A* genes with their respective SNPs in Mexican Americans. *cis*-regulated transcripts are defined as transcripts that contain genetic variation within their gene and regulatory regions that affect their abundance (Göring et al., [@B15]). We found highly significant association of *FADS1*, *FADS2*, and *CPT1A* transcripts with their respective SNPs. These findings in Mexican Americans support our plasma and erythrocyte D5D associations in Alaskan Eskimos, indicating strong support for a significant role of *FADS1*, *FADS2*, and *CPT1A* SNPs in D5D activity. Lack of fatty acid data in the Mexican American population limits our ability to analyze the association of D5D in plasma or erythrocytes for replication purposes but the transcript data provides valuable insight into the role of variants in the regulation of D5D. Another limitation of this study is using estimated indices from individual fatty acids as surrogate measure of desaturase activities. However, studies conducted with desaturases have used product: precursor fatty acids ratio as an estimate or a surrogate measure of desaturase activity (Martinelli et al., [@B24]; Bokor et al., [@B6]; Merino et al., [@B26]), and are now well accepted given the difficulties measuring *in vivo* activities of these enzymes in humans. In addition, we were also able to obtain strong association of SNPs in *FADS1*, *FADS2*, and *CPT1A* with individual fatty acid components.

In summary, we report for the first time the association of liver-specific *CPT1A* SNPs with liver-specific desaturases with a strong statistical support for functional effects. In addition, we replicate the association of *FADS1* and *FADS2* SNPs with desaturase activities and PUFAs in Alaskan Eskimos.
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